Company Analysis Merck & Co
1. Summary
Advantages
- Dividends (2.52%) are higher than the sector average (1.24%).
- The stock's return over the last year (-1.3%) is higher than the sector average (-26.12%).
- The company's current efficiency (ROE=0.9712%) is higher than the sector average (ROE=-80.94%)
Disadvantages
- Price (101.53 $) is higher than fair price (0.8114 $)
- Current debt level 33.13% has increased over 5 years from 30.38%.
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
18 november 17:52 FDA authorizes second COVID-19 antiviral pill, Merck's molnupiravir
18 november 17:27 Merck COVID pill effective, experts will review safety: FDA
18 november 16:45 Merckβs COVID-19 pill heavily used so far despite concerns
2.3. Market efficiency
| Merck & Co | Healthcare | Index | |
|---|---|---|---|
| 7 days | 5.2% | 2.3% | 0.6% |
| 90 days | -12.8% | -36.1% | 7% |
| 1 year | -1.3% | -26.1% | 31.9% |
MRK vs Sector: Merck & Co has outperformed the "Healthcare" sector by 24.82% over the past year.
MRK vs Market: Merck & Co has significantly underperformed the market by -33.19% over the past year.
Stable price: MRK is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: MRK with weekly volatility of -0.0251% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (101.53 $) is higher than the fair price (0.8114 $).
Price is higher than fair: The current price (101.53 $) is 99.2% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (751.54) is higher than that of the sector as a whole (57.99).
P/E vs Market: The company's P/E (751.54) is higher than that of the market as a whole (47.41).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (7.29) is lower than that of the sector as a whole (9.41).
P/BV vs Market: The company's P/BV (7.29) is lower than that of the market as a whole (22.54).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (4.56) is higher than that of the sector as a whole (4.07).
P/S vs Market: The company's P/S indicator (4.56) is lower than that of the market as a whole (15.1).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (40.3) is higher than that of the sector as a whole (17.44).
EV/Ebitda vs Market: The company's EV/Ebitda (40.3) is higher than that of the market as a whole (22.02).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -19.26% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-19.26%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-14.25%).
5.4. ROE
ROE vs Sector: The company's ROE (0.9712%) is higher than that of the sector as a whole (-80.94%).
ROE vs Market: The company's ROE (0.9712%) is lower than that of the market as a whole (16.9%).
5.5. ROA
ROA vs Sector: The company's ROA (0.3422%) is lower than that of the sector as a whole (6.66%).
ROA vs Market: The company's ROA (0.3422%) is lower than that of the market as a whole (6.57%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (22.77%) is higher than that of the sector as a whole (15.68%).
ROIC vs Market: The company's ROIC (22.77%) is higher than that of the market as a whole (9.31%).
7. Dividends
7.1. Dividend yield vs Market
High yield: The dividend yield of the company 2.52% is higher than the average for the sector '1.24%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 2.52% has been steadily paid over the past 7 years, DSI=0.93.
Weak dividend growth: The company's dividend yield 2.52% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (2039.73%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 04.05.2024 | Oosthuizen Johannes Jacobus President, U.S. Market |
Purchase | 127.51 | 116 289 | 912 |
| 04.05.2024 | Klobuchar Michael A EVP - Chief Strategy Officer |
Purchase | 127.51 | 113 101 | 887 |
| 04.05.2024 | DeLuca Richard R. EVP&Pres, Merck Animal Heallth |
Purchase | 127.51 | 3 458 840 | 27 126 |
| 11.03.2024 | Merck & Co., Inc. 10% Owner |
Purchase | 23 | 492 136 000 | 21 397 205 |
| 14.02.2024 | Davis Robert M Chairman, CEO & President |
Sale | 125.4 | 10 661 600 | 85 021 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
